Boule Diagnostics AB Stock OTC Markets
Stocks
BDAB.F
SE0011231158
Advanced Medical Equipment & Technology
OTC Markets Traded| Market Cap | 140M 14.75M 12.76M 11.92M 10.93M 20.56M 1.4B 20.89M 54.87M 704M 55.39M 54.18M 2.33B | P/E 2026 * |
-14.3x | P/E 2027 * | 16.3x |
|---|---|---|---|---|---|
| Enterprise Value | 336M 35.49M 30.7M 28.67M 26.3M 49.46M 3.38B 50.25M 132M 1.69B 133M 130M 5.6B | EV / Sales 2026 * |
0.74x | EV / Sales 2027 * | 0.67x |
| Free-Float |
53.64% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Boule Diagnostics AB
| 1 day | -55.23% |
| Manager | Title | Age | Since |
|---|---|---|---|
Johan Folkunger
CEO | Chief Executive Officer | - | 2026-06-21 |
| Director of Finance/CFO | 54 | 2026-02-10 | |
Lucy Yehiayan
CTO | Chief Tech/Sci/R&D Officer | - | 2018-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 59 | 2013-12-31 | |
| Chairman | 73 | 2020-12-31 | |
| Chairman | 74 | 2022-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -55.23% | -89.53% | - | - | 14.75M | |
| +2.41% | +3.43% | +30.62% | +7.65% | 220B | |
| +2.39% | +5.02% | +3.16% | -19.90% | 144B | |
| +1.36% | +7.21% | -19.37% | +22.50% | 134B | |
| +0.02% | +5.52% | -52.11% | -2.80% | 71.46B | |
| +0.45% | +4.24% | +15.13% | +12.37% | 51.71B | |
| +1.05% | +7.19% | -14.42% | -19.02% | 50.84B | |
| +3.28% | +5.49% | +28.07% | +15.38% | 41.23B | |
| +1.79% | +7.83% | +46.35% | +40.43% | 39.95B | |
| +2.08% | +5.51% | +0.94% | -5.05% | 32.42B | |
| Average | -4.04% | +5.55% | +4.26% | +5.73% | 87.22B | |
| Weighted average by Cap. | +1.79% | +5.17% | +5.04% | +4.31% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 453M 47.81M 41.36M 38.62M 35.43M 66.64M 4.55B 67.7M 178M 2.28B 180M 176M 7.54B | 483M 51M 44.11M 41.2M 37.79M 71.08M 4.85B 72.21M 190M 2.43B 192M 187M 8.04B |
| Net income | -9.77M -1.03M -892K -833K -764K -1.44M -98.14M -1.46M -3.84M -49.19M -3.87M -3.79M -163M | 8.6M 907K 785K 733K 672K 1.26M 86.32M 1.28M 3.37M 43.27M 3.41M 3.33M 143M |
| Net Debt | 197M 20.74M 17.94M 16.75M 15.37M 28.9M 1.97B 29.36M 77.14M 989M 77.88M 76.17M 3.27B | 185M 19.47M 16.84M 15.73M 14.43M 27.14M 1.85B 27.57M 72.42M 929M 73.11M 71.51M 3.07B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
